• Cycloastragenol in Glucocorticoid-Induced ONFH

  2026-09-04

  This in vivo study shows that cycloastragenol reduced femoral-head necrosis and trabecular bone loss in a methylprednisolone-induced rat model of glucocorticoid-induced osteonecrosis of the femoral head. Its central contribution is to connect structural and vascular protection with suppression of osteoclast-associated signaling, supporting further investigation of osteoclast control as a hip-preservation strategy.

• Rotigotine Workflows for Parkinson’s Disease Research

  2026-09-03

  Rotigotine supports receptor-focused cell assays, Parkinson’s disease models, and depression-related behavioral studies in one adaptable workflow. This guide translates dose-response findings into practical controls, delivery strategies, and troubleshooting steps that help separate genuine dopaminergic effects from locomotor confounding.

• Bobcat339: TET Inhibition Meets Bone Epigenetics

  2026-09-03

  A translational framework for using Bobcat339 to interrogate TET1/TET2 biology, DNA methylation regulation, and the UHRF1–super-enhancer–TGM2 axis implicated in senile osteoporosis.

• Captopril: From ACE Inhibition to Assay Design

  2026-09-02

  Captopril is an ACE inhibitor with a well-defined cardiovascular mechanism and valuable applications in hypertension research. This article presents an assay-centered framework linking ACE activity, bradykinin B2 signaling, intestinal motility, and oncology evidence without overstating translational conclusions.

• KN-62 and the Next Logic of Calcium Signaling

  2026-09-02

  A translational perspective on KN-62 as a CaMKII-focused research tool, linking calcium signaling, secretion, metabolism, cell-cycle control, and emerging calcium-dependent autophagy biology while distinguishing established evidence from testable hypotheses.

• Captopril, ACE, and Bradykinin Assay Design

  2026-09-01

  Captopril is an ACE inhibitor whose effects extend beyond angiotensin signaling into bradykinin biology. This article translates guinea pig ileum findings into a rigorous framework for designing and interpreting tissue-reflex assays without overextending the evidence.

• GSTA1, Glutathione Loss, and α-Amanitin Hepatotoxicity

  2026-09-01

  The reference study identifies GSTA1 as an unexpected driver of α-amanitin-induced liver injury rather than solely a protective detoxification enzyme. By combining mouse toxicology, multi-omics, binding assays, and genetic intervention, it links NRF2-associated GSTA1 induction to glutathione depletion, reactive oxygen species accumulation, and hepatocyte death.

• Tubastatin A: HDAC6 Inhibitor Workflows

  2026-08-31

  Tubastatin A combines strong HDAC6 selectivity with a practical pharmacodynamic readout: α-tubulin hyperacetylation. This guide translates cardiac ischemia–reperfusion findings into reproducible workflows for cancer biology, inflammation, neuroprotection, and cell-death studies.

• Bifendate, Autophagy, and Lipid Accumulation

  2026-08-31

  The reference study shows that bifendate inhibits autophagy at several functionally distinct stages, including autophagosome–lysosome fusion, lysosomal acidification, and autophagic lysosome reformation. It also reports reduced oleic acid-induced lipid droplet accumulation, providing a mechanistic framework for investigating how bifendate may influence hepatic lipid handling.

• SB203580 in Oral–Lung Inflammation Research

  2026-08-30

  SB203580 is a powerful tool for p38 MAPK signaling pathway research. This article explains how to use it to dissect the oral–lung inflammatory axis, interpret pathway readouts, and design stronger epithelial–neutrophil assays.

• TAI-1 Hec1 Inhibitor Workflows for Cancer Research

  2026-08-29

  TAI-1 enables mechanism-led studies of Hec1-Nek2 disruption, mitotic misalignment, and apoptotic cell death induction rather than relying on viability data alone. This practical guide connects nanomolar cell assays with combination testing, genotype-aware design, and carefully bounded hypotheses around replication stress.

• A 83-01: ALK-5 Inhibitor for TGF-β Research

  2026-08-28

  A 83-01 is a selective ALK-5 inhibitor that blocks TGF-β-driven Smad-dependent transcription in biochemical and cellular research assays. Its defined potency, receptor profile, solubility limitations, and relevance to organoid workflows make it useful for controlled TGF-β signaling pathway inhibitor studies, but not a substitute for direct validation in every model.

• Pifithrin-α: Decoding p53 in Ferroptosis

  2026-08-28

  Explore how Pifithrin-α, a p53 inhibitor, can distinguish p53-driven ferroptosis from correlated stress responses in environmental neurotoxicity models. This evidence-focused guide translates a recent deltamethrin study into practical assay design, controls, and interpretation strategies.

• Angiotensin I: From Precursor to Translational Signal

  2026-08-27

  A thought-leadership guide to using Angiotensin I as a mechanistically resolved perturbation in renin-angiotensin system research, cardiovascular disease mechanisms, neuroendocrine studies, and antihypertensive drug screening.

• PROTAC Nanoassemblies Sensitize FLASH Radiotherapy

  2026-08-27

  The reference study develops a folate-targeted, redox-responsive PROTAC nanoassembly that releases ARV-771 to degrade BRD4 and improve FLASH radiotherapy in resistant tumors. Its findings connect targeted protein degradation with impaired DNA repair, increased oxidative stress, and enhanced apoptotic and necrotic tumor-cell killing.

7929 records 1/529 page Next 12345 下5页 Last page